Trials / Completed
CompletedNCT01453608
A Study to Compare the Use of Ferric Carboxymaltose With Placebo in Patients With Chronic Heart Failure and Iron Deficiency
A Randomised, Double-blind Controlled Phase 4 Study to Compare the Efficacy and Safety of Intravenous Ferric Carboxymaltose With Placebo in Patients With Chronic Heart Failure and Iron Deficiency
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 304 (actual)
- Sponsor
- Vifor Pharma · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine, relative to placebo, the effect of iron repletion therapy using intravenous (IV) ferric carboxymaltose on exercise capacity in patients with chronic heart failure and iron deficiency.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Ferinject (ferric carboxymaltose) | Subjects will receive Ferinject (ferric carboxymaltose) intravenously on Day 0 |
| DRUG | Placebo (saline) | Subjects will receive Placebo (saline) intravenously on Day 0 |
Timeline
- Start date
- 2011-10-01
- Primary completion
- 2014-02-01
- Completion
- 2015-01-01
- First posted
- 2011-10-18
- Last updated
- 2015-03-18
Locations
2 sites across 2 countries: Poland, Russia
Source: ClinicalTrials.gov record NCT01453608. Inclusion in this directory is not an endorsement.